Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide ...

Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies ...

Trump is “in peak physical and mental condition,” White House Press Secretary Karoline Leavitt told The Atlantic in an ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts. Novo ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

Weight loss can reverse the cardiovascular changes that take place in the heart, but will a new diet and exercise work, or is ...

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...